Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ZEP 3

Next Previous
Search
Drug Profile

ZEP 3

Alternative Names: ZEP-3; ZEP-3Na

Latest Information Update: 08 Aug 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SIS Shulov Innovative Science
  • Class Analgesics; Antivirals; Peptides; Skin disorder therapies
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Herpes labialis
  • No development reported Herpesvirus infections

Most Recent Events

  • 26 Jul 2022 ZEP 3 is still in phase II trial in Atopic dermatitis (In adolescents, In adults, In children, In the elderly) in Israel (Topical) (SIS Shulov Innovative Science)
  • 04 Jun 2019 SIS Shulov Innovative Science plans a phase-II trial in Atopic dermatitis in Israel in Q2 2019 (SIS Shulov Innovative Science pipeline, June 2019)
  • 04 Jun 2019 SIS Shulov Innovative Science intends to schedule a pre-IND meeting with the US FDA in Q1 2019 to initiate phase-III trial in Herpes labialis in USA (SIS Shulov Innovative Science pipeline, June 2019)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top